1
|
Szwiec M, Marciniak W, Derkacz R, Huzarski T, Gronwald J, Cybulski C, Dębniak T, Jakubowska A, Lener MR, Falco M, Kładny J, Baszuk P, Kotsopoulos J, Narod SA, Lubiński J. Serum Levels of Copper and Zinc and Survival in Breast Cancer Patients. Nutrients 2024; 16:1000. [PMID: 38613033 PMCID: PMC11013867 DOI: 10.3390/nu16071000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2024] [Revised: 03/23/2024] [Accepted: 03/25/2024] [Indexed: 04/14/2024] Open
Abstract
There is emerging interest in the relationship between several serum micronutrients and the prognosis of patients with breast cancer. The relationship between serum zinc and copper levels and breast cancer prognosis is unclear. In our study, we included 583 patients with breast cancer diagnosed between 2008 and 2015 in the region of Szczecin, Poland. In a blood sample obtained before treatment, serum zinc and copper levels were quantified by mass spectroscopy. Each patient was assigned to one of four categories (quartiles) based on the distribution of the elements in the entire cohort. Patients were followed from diagnosis to death over a mean of 10.0 years. The 10-year overall survival was 58.3% for women in the highest and 82.1% for those in the lowest quartile of serum copper/zinc ratio (p < 0.001). The multivariate hazard ratio (HR) for breast cancer death was 2.07 (95% CI 1.17-3.63; p = 0.01) for patients in the highest quartile of serum copper/zinc ratio compared to those in the lowest. There is evidence that the serum zinc level and copper/zinc ratio provide an independent predictive value for overall survival and breast cancer-specific survival after breast cancer diagnosis.
Collapse
Affiliation(s)
- Marek Szwiec
- Department of Surgery and Oncology, University of Zielona Góra, Zyty 28, 65-046 Zielona Góra, Poland;
| | - Wojciech Marciniak
- Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland; (W.M.); (R.D.)
| | - Róża Derkacz
- Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland; (W.M.); (R.D.)
| | - Tomasz Huzarski
- Department of Clinical Genetics and Pathology, University of Zielona Góra, ul. Zyty 28, 65-046 Zielona Góra, Poland;
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (J.G.); (C.C.); (T.D.); (A.J.); (M.R.L.); (P.B.)
| | - Jacek Gronwald
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (J.G.); (C.C.); (T.D.); (A.J.); (M.R.L.); (P.B.)
| | - Cezary Cybulski
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (J.G.); (C.C.); (T.D.); (A.J.); (M.R.L.); (P.B.)
| | - Tadeusz Dębniak
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (J.G.); (C.C.); (T.D.); (A.J.); (M.R.L.); (P.B.)
| | - Anna Jakubowska
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (J.G.); (C.C.); (T.D.); (A.J.); (M.R.L.); (P.B.)
| | - Marcin R. Lener
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (J.G.); (C.C.); (T.D.); (A.J.); (M.R.L.); (P.B.)
| | - Michał Falco
- Regional Oncology Centre, 71-730 Szczecin, Poland;
| | - Józef Kładny
- Department of General and Oncological Surgery, Pomeranian Medical University, 71-252 Szczecin, Poland;
| | - Piotr Baszuk
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (J.G.); (C.C.); (T.D.); (A.J.); (M.R.L.); (P.B.)
| | - Joanne Kotsopoulos
- Women’s College Research Institute, Toronto, ON M5S 1B2, Canada; (J.K.); (S.A.N.)
- Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada
| | - Steven A. Narod
- Women’s College Research Institute, Toronto, ON M5S 1B2, Canada; (J.K.); (S.A.N.)
- Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada
| | - Jan Lubiński
- Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra, Poland; (W.M.); (R.D.)
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (J.G.); (C.C.); (T.D.); (A.J.); (M.R.L.); (P.B.)
| |
Collapse
|
2
|
Baszuk P, Marciniak W, Derkacz R, Jakubowska A, Cybulski C, Gronwald J, Dębniak T, Huzarski T, Białkowska K, Pietrzak S, Muszyńska M, Kładny J, Narod SA, Lubiński J, Lener MR. Blood Copper Levels and the Occurrence of Colorectal Cancer in Poland. Biomedicines 2021; 9:biomedicines9111628. [PMID: 34829856 PMCID: PMC8615693 DOI: 10.3390/biomedicines9111628] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Revised: 11/02/2021] [Accepted: 11/02/2021] [Indexed: 01/14/2023] Open
Abstract
There is a need for sensitive and specific biomarkers for the early detection of colorectal cancer. In this retrospective study, we assessed whether a high blood copper level was associated with the presence of colorectal cancer. The blood copper level was measured among 187 colorectal cancer patients and 187 matched controls. Cases and controls were matched for sex, smoking status (yes/no) and year of birth. Among the cases, the mean blood copper level was 1031 µg/L (range 657 µg/L to 2043 µg/L) and among the controls, the mean blood copper level was 864 µg/L (range 589 µg/L to 1433 µg/L). The odds ratio for colorectal cancer for those in the highest quartile of copper level (versus the lowest) was 12.7 (95% CI: 4.98–32.3; p < 0.001). Of the patients with stage I–II colon cancer, 62% had a copper level in the highest quartile. A blood copper level in excess of 930 µg/L is associated with an increase in the prevalence of colorectal cancer in the Polish population and its potential use in early detection programs should be considered.
Collapse
Affiliation(s)
- Piotr Baszuk
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (P.B.); (W.M.); (R.D.); (A.J.); (C.C.); (J.G.); (T.D.); (T.H.); (K.B.); (S.P.); (M.M.); (J.L.)
- Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Grzepnica, Dobra (Szczecińska), Poland
| | - Wojciech Marciniak
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (P.B.); (W.M.); (R.D.); (A.J.); (C.C.); (J.G.); (T.D.); (T.H.); (K.B.); (S.P.); (M.M.); (J.L.)
- Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Grzepnica, Dobra (Szczecińska), Poland
| | - Róża Derkacz
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (P.B.); (W.M.); (R.D.); (A.J.); (C.C.); (J.G.); (T.D.); (T.H.); (K.B.); (S.P.); (M.M.); (J.L.)
- Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Grzepnica, Dobra (Szczecińska), Poland
| | - Anna Jakubowska
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (P.B.); (W.M.); (R.D.); (A.J.); (C.C.); (J.G.); (T.D.); (T.H.); (K.B.); (S.P.); (M.M.); (J.L.)
| | - Cezary Cybulski
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (P.B.); (W.M.); (R.D.); (A.J.); (C.C.); (J.G.); (T.D.); (T.H.); (K.B.); (S.P.); (M.M.); (J.L.)
- Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Grzepnica, Dobra (Szczecińska), Poland
| | - Jacek Gronwald
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (P.B.); (W.M.); (R.D.); (A.J.); (C.C.); (J.G.); (T.D.); (T.H.); (K.B.); (S.P.); (M.M.); (J.L.)
- Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Grzepnica, Dobra (Szczecińska), Poland
| | - Tadeusz Dębniak
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (P.B.); (W.M.); (R.D.); (A.J.); (C.C.); (J.G.); (T.D.); (T.H.); (K.B.); (S.P.); (M.M.); (J.L.)
| | - Tomasz Huzarski
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (P.B.); (W.M.); (R.D.); (A.J.); (C.C.); (J.G.); (T.D.); (T.H.); (K.B.); (S.P.); (M.M.); (J.L.)
- Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Grzepnica, Dobra (Szczecińska), Poland
- Department of Clinical Genetics and Pathology, University of Zielona Góra, ul. Zyty 28, 65-046 Zielona Góra, Poland
| | - Katarzyna Białkowska
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (P.B.); (W.M.); (R.D.); (A.J.); (C.C.); (J.G.); (T.D.); (T.H.); (K.B.); (S.P.); (M.M.); (J.L.)
| | - Sandra Pietrzak
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (P.B.); (W.M.); (R.D.); (A.J.); (C.C.); (J.G.); (T.D.); (T.H.); (K.B.); (S.P.); (M.M.); (J.L.)
| | - Magdalena Muszyńska
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (P.B.); (W.M.); (R.D.); (A.J.); (C.C.); (J.G.); (T.D.); (T.H.); (K.B.); (S.P.); (M.M.); (J.L.)
- Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Grzepnica, Dobra (Szczecińska), Poland
| | - Józef Kładny
- Department of General Surgery and Surgical Oncology, First Clinical Hospital of Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland;
| | - Steven A. Narod
- Women’s College Research Institute, Toronto, ON M5G 1N8, Canada;
- Dalla Lana School of Public Health, University of Toronto, Toronto, ON M5T 3M7, Canada
| | - Jan Lubiński
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (P.B.); (W.M.); (R.D.); (A.J.); (C.C.); (J.G.); (T.D.); (T.H.); (K.B.); (S.P.); (M.M.); (J.L.)
- Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Grzepnica, Dobra (Szczecińska), Poland
| | - Marcin R. Lener
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; (P.B.); (W.M.); (R.D.); (A.J.); (C.C.); (J.G.); (T.D.); (T.H.); (K.B.); (S.P.); (M.M.); (J.L.)
- Correspondence: ; Tel.: +48-91-441-7250
| |
Collapse
|
3
|
Dymek P, Kiełbowski K, Sienkiewicz S, Błaszkowski T, Kudrymska A, Halczak M, Lubikowski J, Kładny J. Leiomyosarcoma in adrenal gland. Endokrynol Pol 2021; 72:674-675. [PMID: 34647613 DOI: 10.5603/ep.a2021.0083] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Revised: 08/27/2021] [Accepted: 09/01/2021] [Indexed: 11/25/2022]
Affiliation(s)
- Przemysław Dymek
- Department of General and Oncological Surgery, Pomeranian Medical University, Szczecin, Poland.
| | - Kajetan Kiełbowski
- Department of General and Oncological Surgery, Pomeranian Medical University, Szczecin, Poland
| | - Sandra Sienkiewicz
- Department of General and Oncological Surgery, Pomeranian Medical University, Szczecin, Poland
| | - Tomasz Błaszkowski
- Department of General and Oncological Surgery, Pomeranian Medical University, Szczecin, Poland
| | | | - Mirosław Halczak
- Department of General and Oncological Surgery, Pomeranian Medical University, Szczecin, Poland
| | - Jerzy Lubikowski
- Department of General and Oncological Surgery, Pomeranian Medical University, Szczecin, Poland
| | - Józef Kładny
- Department of General and Oncological Surgery, Pomeranian Medical University, Szczecin, Poland
| |
Collapse
|
4
|
Sulżyc-Bielicka V, Kołodziejczyk L, Adamska M, Skotarczak B, Jaczewska S, Safranow K, Bielicki P, Kładny J, Bielicki D. Colorectal cancer and Blastocystis sp. infection. Parasit Vectors 2021; 14:200. [PMID: 33853659 PMCID: PMC8048192 DOI: 10.1186/s13071-021-04681-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Accepted: 03/15/2021] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND Blastocystis sp. is a common intestinal protozoan found worldwide. Based on gene analysis, 17 subtypes (STs, ST1-ST17) have been identified, 9 of which have been isolated from humans. Differences in clinical consequences may depend on differences among the STs. Here, we evaluated the prevalence of Blastocystis sp. in patients with colorectal cancer (CRC) compared to a control group and assessed the relationships between Blastocystis sp. infection and sex; age; and CRC grade, stage, and location. METHODS The study included 107 CRC patients (41 women and 66 men, median age 65 years); 124 subjects without colorectal cancer or a history of oncological disease comprised the control group (55 women and 69 men, median age 63). Stool samples were collected from patients before oncological treatment and examined using light microscopy (iodine-stained smear). Additionally, PCR-based identification of Blastocystis sp. was performed in 95 stool samples from CRC patients and 76 stool samples from the control group. RESULTS Light microscopy showed that the prevalence of Blastocystis sp. was significantly higher in CRC patients than in the control group (12.15% and 2.42%, respectively; p = 0.0041). Multivariate analysis showed that the odds of Blastocystis sp. infection were fivefold higher in the CRC group than in the control group. PCR-based molecular examinations demonstrated that the proportion of patients infected with Blastocystis sp. was significantly higher in the CRC group than in the control group (12.63% and 2.63%, respectively; p = 0.023). The predominant ST in the CRC group was ST3, detected in nine patients (75%), followed by ST1 (2 patients, 16.7%) and ST2 (1 patient, 8.3%). No association was found between Blastocystis sp. infection and age, sex, or CRC stage, grade, or location. CONCLUSIONS The results showed that CRC was associated with an increased risk of opportunistic Blastocystis sp. infection, even before oncological treatment. To the best of our knowledge, this is the first report estimating the prevalence of Blastocystis sp. infection in CRC patients before oncological treatment in Europe.
Collapse
Affiliation(s)
| | - Lidia Kołodziejczyk
- Department of Biology and Medical Parasitology, Pomeranian Medical University, Szczecin, Poland
| | | | | | - Sylwia Jaczewska
- Early Phase Clinical Trial Unit. Maria Sklodowska-Curie Memorial Cancer Centre-Institute of Oncology, Warsaw, Poland
| | - Krzysztof Safranow
- Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, Szczecin, Poland
| | - Paweł Bielicki
- Department of Radiotherapy, Pomeranian Medical University, Szczecin, Poland
| | - Józef Kładny
- Department of Oncological Surgery, Pomeranian Medical University, Szczecin, Poland
| | - Dariusz Bielicki
- Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland
| |
Collapse
|
5
|
Błaszkowski T, Kładny J, Al-Amawi T, Kaczmarek K, Kwietniak M, Wojtasik P, Halczak M, Michalak T, Jezierski K, Chmialak M. Factors determining the quality of life in patients undergoing radical surgery due to malignant tumors of the rectum. Pol Przegl Chir 2021; 93:1-5. [PMID: 33949327 DOI: 10.5604/01.3001.0014.8131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
INTRODUCTION Rectal cancer is one of the most common malignancies in developed countries. However, despite the increasingly better preoperative diagnostics, adaptation of surgical techniques to the location and advancement of the tumor, the combination of surgical treatment with neoadjuvant therapy and adjuvant treatment, standardized control tests, Poland still has not obtained satisfactory results regarding long-term survival. In addition, the effects of the therapy often differ significantly from those expected by patients and the doctors treating them. AIM OF THE STUDY To evaluate the effects of rectal cancer treatment among patients of the General and Oncological Surgery Clinic of the Pomeranian Medical University in Szczecin. The impact of numerous factors on postoperative quality of life was analyzed. MATERIAL AND METHODS Between 2007 - 2015, 263 radical resection procedures were performed in patients with diagnosed rectal cancer. Retrospectively, based on medical records, a database was created covering a range of clinical data. Information about death dates of some patients was obtained at the Registry Office in Szczecin. A survey supplementing clinical data and standardized quality of life assessment forms (EORTC QLQ - C30 and CR29) were sent to 120 living patients. A telephone conversation was carried out with some patients who did not respond to the surveys. Finally, data from 90 people was collected, which represents 75% of the patients enrolled in the study. Patients quality of life was assessed using EORTC questionnaire evaluation guides. RESULTS The patients quality of life worsened the most as a result of anorectal dysfunction. Incontinence of gases and stool, urgency and difficulty in defecation were demonstrated primarily in patients undergoing low rectal resection and irradiation. Patients undergoing radiotherapy, as a result of persistent low anterior resection syndrome, were forced to partially or completely withdraw from professional activity and to limit the pursuit of their interests. Their contacts with family, friends and acquaintances have also deteriorated. The presence of the intestinal stoma significantly affected the deterioration of the reception of the body's own image. However, no relation was found between the existence of the fistula and other aspects of the patients everyday life, including functioning in life and social roles. CONCLUSIONS Due to the acceptable postoperative quality of life of patients with fistula and numerous imperfections of sphincter preserving techniques, operations resulting in terminal ostomy should not be considered as an extremity, and in the case of tumors of the lower rectum with unaffected sphincters, they should be considered as alternative methods for low anterior resection.
Collapse
Affiliation(s)
- Tomasz Błaszkowski
- Klinika Chirurgii Ogólnej i Onkologicznej Pomorskiego Uniwersytetu Medycznego, Szczecin, Polska
| | - Józef Kładny
- Klinika Chirurgii Ogólnej i Onkologicznej Pomorskiego Uniwersytetu Medycznego, Szczecin, Polska
| | - Tariq Al-Amawi
- Klinika Chirurgii Ogólnej i Onkologicznej Pomorskiego Uniwersytetu Medycznego, Szczecin, Polska
| | - Krystian Kaczmarek
- Klinika Urologii i Onkologii Urologicznej Pomorskiego Uniwersytetu Medycznego, Szczecin, Polska
| | - Marcin Kwietniak
- Klinika Chirurgii Ogólnej i Onkologicznej Pomorskiego Uniwersytetu Medycznego, Szczecin, Polska
| | - Piotr Wojtasik
- Klinika Chirurgii Ogólnej i Onkologicznej Pomorskiego Uniwersytetu Medycznego, Szczecin, Polska
| | - Mirosław Halczak
- Klinika Chirurgii Ogólnej i Onkologicznej Pomorskiego Uniwersytetu Medycznego, Szczecin, Polska
| | - Tomasz Michalak
- Klinika Chirurgii Ogólnej i Onkologicznej Pomorskiego Uniwersytetu Medycznego, Szczecin, Polska
| | - Karol Jezierski
- Klinika Chirurgii Ogólnej i Onkologicznej Pomorskiego Uniwersytetu Medycznego, Szczecin, Polska
| | - Mariusz Chmialak
- Klinika Chirurgii Ogólnej i Onkologicznej Pomorskiego Uniwersytetu Medycznego, Szczecin, Polska
| |
Collapse
|
6
|
Ciseł B, Pietrzak L, Michalski W, Wyrwicz L, Rutkowski A, Kosakowska E, Cencelewicz A, Spałek M, Polkowski W, Jankiewicz M, Styliński R, Bębenek M, Kapturkiewicz B, Maciejczyk A, Sadowski J, Zygulska J, Zegarski W, Jankowski M, Las-Jankowska M, Toczko Z, Żelazowska-Omiotek U, Kępka L, Socha J, Wasilewska-Tesluk E, Markiewicz W, Kładny J, Majewski A, Kapuściński W, Suwiński R, Bujko K. Long-course preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for clinical T4 and fixed clinical T3 rectal cancer: long-term results of the randomized Polish II study. Ann Oncol 2020; 30:1298-1303. [PMID: 31192355 DOI: 10.1093/annonc/mdz186] [Citation(s) in RCA: 126] [Impact Index Per Article: 31.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
BACKGROUND This trial evaluated whether preoperative short-course radiotherapy and consolidation chemotherapy (CCT) were superior to chemoradiation in rectal cancers with clinical (c)T4 or fixed cT3. Previously, we reported early results showing no differences in the radical surgery rate (primary end point). In the short-course/CCT group, we observed lower acute toxicity of preoperative treatment and better overall survival (OS). We updated results to determine whether the benefit in OS was sustained and to evaluate late complications. PATIENTS AND METHODS Patients with cT4 or fixed cT3 rectal cancer were randomized either to preoperative 5 × 5 Gy and three cycles of FOLFOX4 or to chemoradiation (50.4 Gy with bolus 5-Fu, leucovorin and oxaliplatin). RESULTS Patients (N = 515) were eligible for analysis, 261 in the short-course/CCT group and 254 in the chemoradiation group. The median follow-up was 7.0 years. The difference in OS was insignificant [hazard ratio (HR) 0.90; 95% confidence interval (CI) 0.70-1.15; P = 0.38). However, the difference in early OS favouring short-course/CCT previously reported was observed again, being 9% at 3 years (95% CI 0.5% to 17%). This difference disappeared later; at 8 years OS was 49% in both groups. There was no difference in disease-free survival (HR 0.95; 95% CI 0.75-1.19; P = 0.65) at 8 years 43% versus 41% in the short-course/CCT group versus the chemoradiation group, respectively. The corresponding values for cumulative incidences of local failure and distant metastases did not differ and were HR = 1.08, 95% CI 0.70-1.23, P = 0.60, 35% versus 32% and HR = 1.10, 95% CI 0.68-1.23, P = 0.54, 36% versus 34%, respectively. The rate of late complications was similar (P = 0.66), grade 3+ being 11% versus 9% in the short-course/CCT group versus the chemoradiation group, respectively. CONCLUSION The superiority of preoperative short-course/CCT over chemoradiation was not demonstrated. CLINICAL TRIAL NUMBER The trial is registered as ClinicalTrials.gov number NCT00833131.
Collapse
Affiliation(s)
- B Ciseł
- Department of Surgical Oncology, Medical University of Lublin, Lublin
| | | | | | | | - A Rutkowski
- Gastroenterological Oncology, M. Skłodowska-Curie Memorial Cancer Centre, Warsaw
| | - E Kosakowska
- Gastroenterological Oncology, M. Skłodowska-Curie Memorial Cancer Centre, Warsaw
| | - A Cencelewicz
- Gastroenterological Oncology, M. Skłodowska-Curie Memorial Cancer Centre, Warsaw
| | | | - W Polkowski
- Department of Surgical Oncology, Medical University of Lublin, Lublin
| | - M Jankiewicz
- Department of Surgical Oncology, Medical University of Lublin, Lublin; Department of Radiotherapy, St. John's Cancer Center, Lublin
| | - R Styliński
- 1st Department of General Surgery, Transplantology and Nutritional Therapy Medical University of Lublin
| | | | | | - A Maciejczyk
- Radiotherapy, Silesian Oncological Centre, Wrocław
| | - J Sadowski
- Department of Radiotherapy, Regional Oncological Centre, Kielce
| | - J Zygulska
- Department of Radiotherapy, Beskid Centre of Oncology, Bielsko-Biala
| | | | | | - M Las-Jankowska
- Clinical Oncology, Collegium Medicum Nicolaus Copernicus University and Oncology Centre, Bydgoszcz
| | - Z Toczko
- Department of Surgery, Regional Hospital, Elblag
| | | | - L Kępka
- Department of Radiotherapy, Military Institute of Medicine, Warsaw
| | - J Socha
- Department of Radiotherapy, Military Institute of Medicine, Warsaw; Department of Radiotherapy, Regional Oncology Center, Czestochowa
| | - E Wasilewska-Tesluk
- Radiotherapy Department, Public Health Care Facility of the Ministry of the Interior and Warmian-Masurian Oncology Centre, Olsztyn; Department of Oncology, University of Warmia and Mazury, Olsztyn
| | - W Markiewicz
- Department of Surgery, Regional Cancer Centre, Białystok
| | - J Kładny
- Department of General Surgery and Surgical Oncology First Clinical Hospital of Pomeranian Medical University, Szczecin
| | - A Majewski
- Department of Surgery, Regional Hospital, Wałbrzych
| | - W Kapuściński
- Department of Radiotherapy, Regional Cancer Centre, Copernicus Memorial Hospital of Łódź, Łódź
| | - R Suwiński
- Department of Radiotherapy, M. Skłodowska-Curie Memorial Cancer Centre, Gliwice, Poland
| | - K Bujko
- II Department of Radiotherapy.
| | | |
Collapse
|
7
|
Sulżyc-Bielicka V, Kołodziejczyk L, Jaczewska S, Bielicki D, Safranow K, Bielicki P, Kładny J, Rogowski W. Colorectal cancer and Cryptosporidium spp. infection. PLoS One 2018; 13:e0195834. [PMID: 29672572 PMCID: PMC5908144 DOI: 10.1371/journal.pone.0195834] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2018] [Accepted: 04/01/2018] [Indexed: 01/06/2023] Open
Abstract
Transient or constant impaired immunity is often associated with neoplastic disease or oncological treatment. Among the most common pathogens found in patients with HIV or patients undergoing chemotherapy are protozoans of the Cryptosporidium genus, which cause diarrhea in humans and animals. The present study determined the frequency of Cryptosporidium spp. infections in patients with colorectal cancer (N = 108; 42 women; 66 men; median age, 65 years), before beginning oncological treatment, compared to a control group (N = 125; 56 women, 69 men; median age, 63 years) without colorectal cancer or a history of oncological disease. We also assessed whether Cryptosporidium spp. infections were associated with age, gender, cancer stage (based on Astler-Coller or TNM classification), histological grade, or cancer location. Patients were treated at the Pomeranian Medical University, in 2009-2014. The presence of Cryptosporidium spp. antigen was determined in stool samples, analyzed with a commercial immunoenzymatic test. Cryptosporidium spp. infections occurred significantly more often (p = 0.015) in patients (13%) compared to controls (4%). The patient group showed no significant relationship between Cryptosporidium spp. infection and sex, age, tumor location, cancer grade, or stage. A multivariate logistic regression analysis adjusted for age and sex that included all subjects (patient + control groups, n = 233) showed that the odds of a Cryptosporidium spp. infection were more than three-fold higher in patients than in controls, and more than six-fold higher among men than among women. CONCLUSIONS 1) Cryptosporidium spp. infections occurred significantly more frequently in patients with colorectal cancer (before oncological treatment) compared to controls, independent of age and sex. 2) Cryptosporidium spp. infections were not associated with the colorectal cancer stage, grade, or location or with patient age. 3) Male gender was significantly related to the frequency of Cryptosporidium spp. infections, independent of age and the presence of colorectal cancer.
Collapse
Affiliation(s)
| | - Lidia Kołodziejczyk
- Chair and Department of Biology and Medical Parasitology, Pomeranian Medical University, Szczecin, Poland
| | - Sylwia Jaczewska
- Department of Clinical Oncology, Public Hospital, Szczecin, Poland
| | - Dariusz Bielicki
- Department of Gastroenterology, Pomeranian Medical University, Szczecin, Poland
| | - Krzysztof Safranow
- Department of Biochemistry and Medical Chemistry, Pomeranian Medical University, Szczecin, Poland
| | | | - Józef Kładny
- Department of General and Oncological Surgery, Pomeranian Medical University, Szczecin, Poland
| | | |
Collapse
|
8
|
Cybulski C, Kluźniak W, Huzarski T, Wokołorczyk D, Kashyap A, Jakubowska A, Szwiec M, Byrski T, Dębniak T, Górski B, Sopik V, Akbari MR, Sun P, Gronwald J, Narod SA, Lubiński J, Dębniak T, Dymerska D, Kurzawski G, Lubiński J, Dymerska D, Tutlewska K, Kuswik M, Rudnicka H, Scott RJ, Billings R, Pławski A, Lubinski J, Kurzawski G, Gromowski T, Kąklewski K, Marciniak W, Durda K, Lener M, Sukiennicki G, Kaczmarek K, Jaworska-Bieniek K, Paszkowska-Szczur K, Waloszczyk P, Lubiński J, Dębniak T, Gronwald J, Hemminki K, Försti A, Huzarski T, Gronwald J, Cybulski C, Oszurek O, Szwiec M, Gugała K, Stawicka M, Morawiec Z, Mierzwa T, Falco M, Janiszewska H, Kilar E, Marczyk E, Kozak-Klonowska B, Siołek M, Surdyka D, Wiśniowski R, Posmyk M, Domagała P, Byrski T, Sun P, Lubiński J, Narod SA, Imyanitov EN, Kaczmarek K, Muszyńska M, Marciniak W, Sukiennicki G, Lener M, Durda K, Jaworska-Bieniek K, Gromowski T, Prajzendanc K, Peruga N, Huzarski T, Byrski T, Gronwald J, Cybulski C, Dębniak T, Morawski A, Jakubowska A, Lubiński J, Lener MR, Scott RJ, Kluźniak W, Gronwald J, Baszuk P, Cybulski C, Wiechowska-Kozłowska A, Huzarski T, Kładny J, Pietrzak S, Soluch A, Jakubowska A, Lubiński J, Plawski A, Prajzendanc K, Jakubowska A, Lubiński J, Rashid UR, Naeemi H, Muhammad N, Lubiński J, Jakubowska A, Loya A, Yusuf MA, Savanevich A, Aszurek O, Gronwald J, Lubiński J, Mathe A, Wong-Brown M, Locke W, Stirzaker C, Braye SG, Forbes JF, Clark S, Avery-Kiejda K, Scott RJ, Tomiczek-Szwiec J, Huzarski T, Szwiec M, Gronwald J, Cybulski C, Marczyk E, Jakubowicz J, Kilar E, Sibilski R, Stawicka M, Morawiec Z, Mierzwa T, Falco M, Janiszewska H, Kozak-Klonowska B, Siołek M, Surdyka D, Wiśniowski R, Posmyk R, Domagała P, Lubiński J, Szwiec M, Tomiczek-Szwiec J, Huzarski T, Cybulski C, Lubiński J. Meeting abstracts from the Annual Conference on Hereditary Cancers 2016. Hered Cancer Clin Pract 2017. [PMCID: PMC5731602 DOI: 10.1186/s13053-017-0081-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
9
|
Kwietniak M, Al-Amawi T, Błaszkowski T, Sulżyc-Bielicka V, Kładny J. The usefulness of D-dimer in diagnosis and prediction of venous thromboembolism in patients with abdominal malignancy. Pol Przegl Chir 2017; 89:27-30. [PMID: 28703112 DOI: 10.5604/01.3001.0010.1018] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
THE AIM of the study was to evaluate the usefulness of D-dimer evaluation in the diagnosis and prediction of venous thromboembolism (VTE) of lower extremities in patients operated on for abdominal tumors depending on the chosen cut-off point for this parameter. MATERIAL AND METHODS We included 150 patients operated on for abdominal cancer in our department between October 2014 and June 2016. In these patients, concentration of D-dimer was determined, medical histories were taken, and physical examinations were performed. Ultrasound exams of the veins of the lower limbs were performed three times in every patient in order to confirm or exclude VTE. RESULTS When a standard cut-off point (500 ng/ml) was used, in 46% of cancer patients D-dimer values were elevated despite the lack of VTE. We did not detect any influence of cancer stage on the value of D-dimer. However, if cut-off point was 1440 ng/ml, which has been suggested in the literature, only 14% of patients were false positive. When the upper cut-off value for D-dimer was raised, the effect of cancer stage on the value of this parameter could be seen. CONCLUSION The concentration of D-dimer is often elevated in patients with active cancer, but is not a sufficient criterion for diagnosis of VTE. The concentration of D-dimer before surgery does not determine the risk of postoperative thromboembolic complications. This is undoubtedly related to the widespread use of effective thromboprophylaxis. According to the literature, ultrasound is the optimum method for detection of VTE in surgically treated cancer patients. The effect of cancer stage on the value of D-dimer is revealed only when the cut-off point in this group is 1440 ng/ml, instead of 500 ng/ml which is used for the general population.
Collapse
Affiliation(s)
- Marcin Kwietniak
- Klinika Chirurgii Ogólnej i Onkologicznej Pomorskiego Uniwersytetu Medycznego w Szczecinie; Kierownik: prof. dr hab. Józef Kładny
| | - Tariq Al-Amawi
- Klinika Chirurgii Ogólnej i Onkologicznej Pomorskiego Uniwersytetu Medycznego w Szczecinie; Kierownik: prof. dr hab. Józef Kładny
| | - Tomasz Błaszkowski
- Klinika Chirurgii Ogólnej i Onkologicznej Pomorskiego Uniwersytetu Medycznego w Szczecinie; Kierownik: prof. dr hab. Józef Kładny
| | - Violetta Sulżyc-Bielicka
- Samodzielna Pracownia Onkologii Klinicznej Pomorskiego Uniwersytetu Medycznego w Szczecinie; Kierownik: dr hab. Violetta Sulżyc-Bielicka, prof. PUM
| | - Józef Kładny
- Department of General and Oncological Surgery, Pomeranian Medical University in Szczecin
| |
Collapse
|
10
|
Karpińska A, Safranow K, Kładny J, Sulżyc-Bielicka V. The Influence Of Obesity On Results Of AT (Doxorubicin Plus Docetaxel) Neoadjuvant Chemotherapy In Locally Advanced Breast Cancer Patients. Pol Przegl Chir 2017; 87:231-7. [PMID: 26172162 DOI: 10.1515/pjs-2015-0047] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2015] [Indexed: 11/15/2022]
Abstract
UNLABELLED The achieve pathologic complete response is proven to be the most important parameter of prognosis. Thereports evaluating the impact of obesity on the obtained pathologic response to chemotherapy are unequal. The aim of the study was to evaluate in locally advanced breast cancer patients, treated with AT(doxorubicin plus docetaxel) neoadjuvant chemotherapy: 1. The relationship of obesity with obtaining pathological response. 2. The relationship of obesity and free of disease recurrence survival (DFS) and overall survival (OS) associated with the tumour. MATERIAL AND METHODS A retrospective study was carried out in a group of 105 patients with locally advanced breast cancer, treated with AT neoadjuvant chemotherapy and then treated with radical surgery. Two variants of pathological response have been adopted: a pCR (T0N0) and pCR1 (TisN0, TxN1, T1N0, T1N1, T0N1). The relationship of obesity with pathological response and survival was investigated. RESULTS In univariate analysis the pCR1 was obtained with its arising from the borderline of statistical significance with lower incidence of obesity. In pCR1 multivariate analysis, negative pCR1 relationship with obesity was on the borderline of the statistical significance. The multivariate analysis showed a significant negative association OS with obesity (p=0.047) and positive with the occurrence of menopause (p = 0.029). CONCLUSIONS In patients with locally advanced breast cancer treated with AT neoadjuvant chemotherapy. 1. Obesity seems to be an independent and unfavourable predictor of the lack of obtaining pCR1 pathological response 2. In the multivariate analysis, the obesity was a significant independent factor related to shorter OS.
Collapse
|
11
|
Lener MR, Scott RJ, Kluźniak W, Baszuk P, Cybulski C, Wiechowska-Kozłowska A, Huzarski T, Byrski T, Kładny J, Pietrzak S, Soluch A, Jakubowska A, Lubiński J. Do founder mutations characteristic of some cancer sites also predispose to pancreatic cancer? Int J Cancer 2016; 139:601-6. [PMID: 27038244 DOI: 10.1002/ijc.30116] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2016] [Revised: 03/11/2016] [Accepted: 03/14/2016] [Indexed: 01/08/2023]
Abstract
Understanding of the etiology and risk of pancreatic cancer (PaCa) is still poorly understood. This study evaluated the prevalence of 10 Polish founder mutations in four genes among PaCa patients and assessed their possible association with the risk of disease in Poland. In the study 383 PaCa patients and 4,000 control subjects were genotyped for founder mutations in: BRCA1 (5382insC, 4153delA, C61G), CHEK2 (1100delC, IVS2 + 1G > A, del5395, I157T), NBS1 (657del5) and PALB2 (509_510delGA, 172_175delTTGT). A statistically significant association between the 657del5 mutation and an increased risk of pancreatic cancer was observed for NBS1 gene. The Slavic NBS1 gene mutation (657delACAAA) was detected in 8 of 383 (2.09%) unselected cases compared with 22 of 4,000 (0.55%) controls (OR: 3.80, p = 0.002). The PALB2 509_510delGA and 172_175delTTGT mutations combined were seen in 2 (0.52%) unselected cases of PaCa and in 8 (0.20%) of 4,000 controls (OR: 2.61, p = 0.49). For BRCA1, the three mutations combined were detected in 4 of 383 (1.04%) PaCa patients and in 17 of 4,000 (0.42%) controls (OR: 2.46, p = 0.20). CHEK2 mutations were not associated with the risk of pancreatic cancer (OR: 1.11, p = 0.72). The founder mutation in NBS1 (657del5) was associated with an increased risk of PaCa in heterozygous carriers, indicating that this mutation appears to predispose to cancer of the pancreas. By identifying pancreatic cancer risk groups, founder mutation testing in Poland should be considered for people at risk for PaCa.
Collapse
Affiliation(s)
- Marcin R Lener
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Połabska 4, Szczecin, 70-115, Poland
| | - Rodney J Scott
- Discipline of Medical Genetics, School of Biomedical Sciences, Faculty of Health, University of Newcastle and the Hunter Medical Research Institute, Newcastle, NSW, 2308, Australia
| | - Wojciech Kluźniak
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Połabska 4, Szczecin, 70-115, Poland
| | - Piotr Baszuk
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Połabska 4, Szczecin, 70-115, Poland
| | - Cezary Cybulski
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Połabska 4, Szczecin, 70-115, Poland
| | - Anna Wiechowska-Kozłowska
- Division of Heath Care Ministry of Internal Affairs and Administration, Laboratory of Endoscopy, Jagiellońska 44, Szczecin, 70-382, Poland
| | - Tomasz Huzarski
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Połabska 4, Szczecin, 70-115, Poland
| | - Tomasz Byrski
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Połabska 4, Szczecin, 70-115, Poland
| | - Józef Kładny
- Department of General and Oncological Surgery, Pomeranian Medical University, Al. Powstańców Wlkp. 72, 70-111, Poland, Szczecin
| | - Sandra Pietrzak
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Połabska 4, Szczecin, 70-115, Poland
| | - Agnieszka Soluch
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Połabska 4, Szczecin, 70-115, Poland
| | - Anna Jakubowska
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Połabska 4, Szczecin, 70-115, Poland
| | - Jan Lubiński
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Połabska 4, Szczecin, 70-115, Poland
| |
Collapse
|
12
|
Lener MR, Scott RJ, Wiechowska-Kozłowska A, Serrano-Fernández P, Baszuk P, Jaworska-Bieniek K, Sukiennicki G, Marciniak W, Muszyńska M, Kładny J, Gromowski T, Kaczmarek K, Jakubowska A, Lubiński J. Serum Concentrations of Selenium and Copper in Patients Diagnosed with Pancreatic Cancer. Cancer Res Treat 2015; 48:1056-64. [PMID: 26727715 PMCID: PMC4946347 DOI: 10.4143/crt.2015.282] [Citation(s) in RCA: 60] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2015] [Accepted: 12/16/2015] [Indexed: 02/07/2023] Open
Abstract
Purpose Understanding of the etiology and pathogenesis of pancreatic cancer (PaCa) is still insufficient. This study evaluated the associations between concentrations of selenium (Se) and copper (Cu) in the serum of PaCa patients. Materials and Methods The study included 100 PaCa patients and 100 control subjects from the same geographical region in Poland. To determine the average concentration of Se, Cu, and ratio Cu:Se in the Polish population, assay for Se and Cu was performed in 480 healthy individuals. Serum levels of Se and Cu were measured using inductively coupled plasma mass spectrometry. Results In the control group, the average Se level was 76 µg/L and Cu 1,098 µg/L. The average Se level among PaCa patients was 60 µg/L and the mean Cu level was 1,432 µg/L. The threshold point at which any decrease in Se concentration was associated with PaCa was 67.45 µg/L. The threshold point of Cu level above which there was an increase in the prevalence of PaCa was 1,214.58 µg/L. In addition, a positive relationship was observed between increasing survival time and Se plasma level. Conclusion This retrospective study suggests that low levels of Se and high levels of Cu might influence development of PaCa and that higher levels of Se are associated with longer survival in patients with PaCa. The results suggest that determining the level of Se and Cu could be incorporated into a risk stratification scheme for the selection and surveillance control examination to complement existing screening and diagnostic procedures.
Collapse
Affiliation(s)
- Marcin R Lener
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Rodney J Scott
- Discipline of Medical Genetics, School of Biomedical Sciences, Faculty of Health, University of Newcastle and The Hunter Medical Research Institute, Newcastle, New South Wales, Australia
| | - Anna Wiechowska-Kozłowska
- Laboratory of Endoscopy, Division of Heath Care Ministry of Internal Affairs and Administration, Szczecin, Poland
| | - Pablo Serrano-Fernández
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Piotr Baszuk
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Katarzyna Jaworska-Bieniek
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Grzegorz Sukiennicki
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Wojciech Marciniak
- Read-Gene S.A., Grzepnica, Pomeranian Medical University, Szczecin, Poland
| | | | - Józef Kładny
- Department of General and Oncological Surgery, Pomeranian Medical University, Szczecin, Poland
| | - Tomasz Gromowski
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Katarzyna Kaczmarek
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Anna Jakubowska
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Jan Lubiński
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.,Read-Gene S.A., Grzepnica, Pomeranian Medical University, Szczecin, Poland
| |
Collapse
|
13
|
Paszkowska-Szczur K, Scott RJ, Górski B, Cybulski C, Kurzawski G, Dymerska D, Gupta S, van de Wetering T, Masojć B, Kashyap A, Gapska P, Gromowski T, Kładny J, Lubiński J, Dębniak T. Polymorphisms in nucleotide excision repair genes and susceptibility to colorectal cancer in the Polish population. Mol Biol Rep 2014; 42:755-64. [PMID: 25391773 PMCID: PMC4330403 DOI: 10.1007/s11033-014-3824-z] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2013] [Accepted: 11/08/2014] [Indexed: 12/14/2022]
Abstract
Xeroderma pigmentosum (XP) is a rare autosomal recessive disease that is associated with a severe deficiency in nucleotide excision repair. Genetic polymorphisms in XP genes may be associated with a change in DNA repair capacity, which could be associated with colorectal cancer development. We assessed the association between 94 single nucleotide polymorphisms (SNPs) within seven XP genes (XPA-XPG) and the colorectal cancer risk in the Polish population. We genotyped 758 unselected patients with colorectal cancer and 1,841 healthy adults. We found that a significantly decreased risk of colorectal cancer was associated with XPC polymorphism rs2228000_CT genotype (OR 0.59; p < 0.0001) and the rs2228000_TT genotype (OR 0.29; p < 0.0001) compared to the reference genotype (CC). And an increased disease risk was associated with the XPD SNP, rs1799793_AG genotype (OR 1.44, p = 0.018) and rs1799793_AA genotype (OR 3.31, p < 0.0001) compared to the reference genotype. Haplotype analysis within XPC, XPD and XPG revealed haplotypes associated with an altered colorectal cancer risk. Stratified analysis by gender showed differences between the association of three SNPs: XPC rs2228000, XPD rs1799793 and XPD rs238406 in females and males. Association analysis between age of disease onset and polymorphisms in XPD (rs1799793) and XPC (rs2228000) revealed differences in the prevalence of these variants in patients under and over 50 years of age. Our results confirmed that polymorphisms in XPC and XPD may be associated with the risk of colorectal cancer.
Collapse
Affiliation(s)
- Katarzyna Paszkowska-Szczur
- Department of Genetics and Pathomorphology, International Hereditary Cancer Center, Pomeranian Medical University, Polabska 4, Szczecin, Poland,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Smereczyński A, Starzyńska T, Kołaczyk K, Kładny J. Role of sonography in assessing complications after laparoscopic cholecystectomy. J Ultrason 2014; 14:152-62. [PMID: 26674247 PMCID: PMC4579702 DOI: 10.15557/jou.2014.0015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2013] [Revised: 05/28/2013] [Accepted: 06/20/2013] [Indexed: 01/04/2023] Open
Abstract
Laparoscopic cholecystectomy, which was introduced to the arsenal of surgical procedures in the middle of the 1980s, is a common alternative for conventional cholecystectomy. Its primary advantage is less invasive character which entails shorter hospitalization and faster recovery. Nevertheless, the complications of both procedures are comparable and encompass multiple organs and tissues. The paper presents ultrasound presentation of the surgical bed after laparoscopic cholecystectomy and of complications associated with this procedure. In the first week following the surgery, the presence of up to 60 ml of fluid in the removed gallbladder bed should be considered normal in certain patients. The fluid will gradually absorb. In single cases, slight amounts of fluid are detected in the peritoneal cavity, which also should not be alarming. Carbon dioxide absorbs from the peritoneal cavity within two days. Ultrasound assessment of the surgical bed after cholecystectomy is inhibited by hemostatic material left during the surgery. Its presentation may mimic an abscess. In such cases, the decisive examination is magnetic resonance imaging but not computed tomography. On the other hand, rapidly accumulating fluid around the liver is an alarming symptom, particularly when there is inadequate blood supply or when peritoneum irritation symptoms develop. Depending on the suspected cause of the patient's deteriorating condition, it is essential to perform urgent computed tomography angiography, celiac angiography or endoscopic retrograde cholangiopancreatography or magnetic resonance cholangiopancreatography. The character of the fluid collection may be determined by its ultrasound-guided puncture. This procedure allows for aspiration of fluid and placement of a drain. Moreover, transabdominal ultrasound examination after laparoscopic cholecystectomy may contribute to the identification of: dropped stones in the right hypochondriac region, residual fragment of the gallbladder with possible concretions, undiagnosed choledocholithiasis, existing cholestasis, pseudoaneurysm of the hepatic artery, portal vein thrombosis and hematoma as well as hernias of the abdominal walls. Moreover, ultrasound examination helps to identify optimal sites in the abdominal integuments, which enables collision-free access to the peritoneal cavity.
Collapse
Affiliation(s)
| | - Teresa Starzyńska
- Klinika Gastrologii, Pomorski Uniwersytet Medyczny, Szczecin, Polska
| | - Katarzyna Kołaczyk
- Zakład Diagnostyki Obrazowej i Radiologii Interwencyjnej, Pomorski Uniwersytet Medyczny, Szczecin, Polska
| | - Józef Kładny
- Klinika Chirurgii Ogólnej i Onkologicznej, Pomorski Uniwersytet Medyczny, Szczecin, Polska
| |
Collapse
|
15
|
Gromowski T, Masojć B, Scott RJ, Cybulski C, Górski B, Kluźniak W, Paszkowska-Szczur K, Rozmiarek A, Dębniak B, Maleszka R, Kładny J, Lubiński J, Dębniak T. Prevalence of the E318K and V320I MITF germline mutations in Polish cancer patients and multiorgan cancer risk-a population-based study. Cancer Genet 2014; 207:128-32. [PMID: 24767713 DOI: 10.1016/j.cancergen.2014.03.003] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2013] [Revised: 02/17/2014] [Accepted: 03/07/2014] [Indexed: 10/25/2022]
Abstract
The E318K mutation in the MITF gene has been associated with a high risk of melanoma, renal cell carcinoma, and pancreatic cancer; the risk of other cancers has not been evaluated so far. Herein, we examined the possible association of E318K and a novel variant of the MITF gene, V320I, with the risk of cancers of different sites of origin in a Polish population. We assayed for the presence of the E318K and V320I missense mutations in 4,226 patients with one of six various cancers (melanoma or cancer of the kidney, lung, prostate, colon, or breast) and 2,114 controls from Poland. The E318K mutation was detected in 4 of 2,114 participants (0.19%) in the Polish control population, the V320I in 3 of 2,114 participants (0.14%) in the control group. We found no statistically significant differences in the prevalence of the E318K and V320I variants among cases and controls. We found two carriers of the E318K variant among melanoma patients (P = 0.95), one carrier among breast cancer patients (P = 0.77), one carrier among colorectal cancer patients (P = 0.82), and one carrier among kidney cancer patients (P = 0.64). Our study demonstrates a lack of strong association of E318K and V320I with increased risk of melanoma or cancers of the kidney, breast, prostate, lung, or colon.
Collapse
Affiliation(s)
- Tomasz Gromowski
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
| | - Bartłomiej Masojć
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Rodney J Scott
- Discipline of Medical Genetics, Faculty of Health, University of Newcastle and Hunter Medical Research Institute, Newcastle, NSW, Australia
| | - Cezary Cybulski
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Bohdan Górski
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Wojciech Kluźniak
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Katarzyna Paszkowska-Szczur
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | | | - Bogusław Dębniak
- Chair and Clinic of Mother's and Child's Health, Medical University, Poznań, Poland
| | - Romuald Maleszka
- Department of Dermatology and Venereology, Pomeranian Medical University, Szczecin, Poland
| | - Józef Kładny
- Department of General and Oncological Surgery, Pomeranian Medical University, Szczecin, Poland
| | - Jan Lubiński
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Tadeusz Dębniak
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| |
Collapse
|
16
|
Smereczyński A, Starzyńska T, Kołaczyk K, Kładny J. Tissue reactions of abdominal integuments to surgical sutures in sonography. J Ultrason 2014; 14:21-7. [PMID: 26675029 PMCID: PMC4579726 DOI: 10.15557/jou.2014.0002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2013] [Revised: 12/20/2013] [Accepted: 12/27/2013] [Indexed: 11/30/2022] Open
Abstract
Classical abdominal surgeries usually require long incisions of the abdominal integuments followed by tight closure with adequate suturing material. Nonabsorbable sutures may cause various reactions, including granuloma reactions, both sterile and inflammatory.
Collapse
Affiliation(s)
| | - Teresa Starzyńska
- Klinika Gastrologii, Pomorski Uniwersytet Medyczny, Szczecin, Polska
| | - Katarzyna Kołaczyk
- Zakład Diagnostyki Obrazowej i Radiologii Interwencyjnej, Pomorski Uniwersytet Medyczny, Szczecin, Polska
| | - Józef Kładny
- Klinika Chirurgii Ogólnej i Onkologicznej, Pomorski Uniwersytet Medyczny, Szczecin, Polska
| |
Collapse
|
17
|
Dymerska D, Kurzawski G, Suchy J, Roomere H, Toome K, Metspalu A, Janavičius R, Elsakov P, Irmejs A, Berzina D, Miklaševičs E, Gardovskis J, Rebane E, Kelve M, Kładny J, Huzarski T, Gronwald J, Dębniak T, Byrski T, Stembalska A, Surdyka D, Siołek M, Szwiec M, Banaszkiewicz Z, Wiśniowski R, Kilar E, Scott R, Lubiński J. Lynch syndrome mutations shared by the Baltic States and Poland. Clin Genet 2013; 86:190-3. [DOI: 10.1111/cge.12251] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2013] [Revised: 08/07/2013] [Accepted: 08/07/2013] [Indexed: 11/30/2022]
Affiliation(s)
- D. Dymerska
- Department of Genetics and Pathology, International Hereditary Cancer Center; Pomeranian Medical University; Szczecin Poland
| | - G. Kurzawski
- Department of Genetics and Pathology, International Hereditary Cancer Center; Pomeranian Medical University; Szczecin Poland
| | - J. Suchy
- Department of Genetics and Pathology, International Hereditary Cancer Center; Pomeranian Medical University; Szczecin Poland
| | | | - K. Toome
- Insitute of Biomedicine, Faculty of Medicine; University of Tartu; Tartu Estonia
| | - A. Metspalu
- The Estonian Academy of Sciences; Tallinn Estonia
- Institute of Molecular and Cell Biology
- Estonian Genome Centre of University of Tartu; University of Tartu; Tartu Estonia
| | - R. Janavičius
- Department of Molecular and Regenerative Medicine; Hematology, Oncology and Transfusion Medicine Center; Vilnius University Hospital Santariskiu Clinics; Vilnius Lithuania
- State Research Institute; Innovative Medicine Center; Vilnius Lithuania
| | - P. Elsakov
- State Research Institute; Innovative Medicine Center; Vilnius Lithuania
| | - A. Irmejs
- Hereditary Cancer Institute; Riga Stradins University; Riga Latvia
- Pauls Stradins Clinical University Hospital; Riga Latvia
| | - D. Berzina
- Hereditary Cancer Institute; Riga Stradins University; Riga Latvia
- Pauls Stradins Clinical University Hospital; Riga Latvia
| | - E. Miklaševičs
- Hereditary Cancer Institute; Riga Stradins University; Riga Latvia
- Pauls Stradins Clinical University Hospital; Riga Latvia
| | - J. Gardovskis
- Hereditary Cancer Institute; Riga Stradins University; Riga Latvia
- Pauls Stradins Clinical University Hospital; Riga Latvia
| | - E. Rebane
- Competence Centre for Cancer Research; Tallinn Estonia
| | - M. Kelve
- Department of Gene Technology; Tallinn University of Technology; Tallinn Estonia
| | - J. Kładny
- Department of Genetics and Pathology, International Hereditary Cancer Center; Pomeranian Medical University; Szczecin Poland
| | - T. Huzarski
- Department of Genetics and Pathology, International Hereditary Cancer Center; Pomeranian Medical University; Szczecin Poland
| | - J. Gronwald
- Department of Genetics and Pathology, International Hereditary Cancer Center; Pomeranian Medical University; Szczecin Poland
| | - T. Dębniak
- Department of Genetics and Pathology, International Hereditary Cancer Center; Pomeranian Medical University; Szczecin Poland
| | - T. Byrski
- Department of Genetics and Pathology, International Hereditary Cancer Center; Pomeranian Medical University; Szczecin Poland
| | - A. Stembalska
- Department of Genetics; Medical University; Wrocław Poland
| | - D. Surdyka
- Radiotherapy Department with Therapy and Brachytherapy Unit; Oncology Center; Lublin Poland
| | - M. Siołek
- Holy Cross Oncology Center; Kielce Poland
| | - M. Szwiec
- Regional Oncology Center; Opole Poland
| | - Z. Banaszkiewicz
- Department of Surgery, Collegium Medicum; Nicolaus Copernicus University; Bydgoszcz Poland
| | | | - E. Kilar
- Regional Oncology Center; Świdnica Poland
| | - R.J. Scott
- Department of Genetics and Pathology, International Hereditary Cancer Center; Pomeranian Medical University; Szczecin Poland
- Discipline of Medical Genetics, Faculty of Health; University of Newcastle and the Hunter Medical Research Institute; Newcastle Australia
- Division of Genetics, Hunter Area Pathology Service; John Hunter Hospital; Newcastle Australia
| | - J. Lubiński
- Department of Genetics and Pathology, International Hereditary Cancer Center; Pomeranian Medical University; Szczecin Poland
| |
Collapse
|
18
|
Lener MR, Gupta S, Scott RJ, Tootsi M, Kulp M, Tammesoo ML, Viitak A, Metspalu A, Serrano-Fernández P, Kładny J, Jaworska-Bieniek K, Durda K, Muszyńska M, Sukiennicki G, Jakubowska A, Lubiński J. Can selenium levels act as a marker of colorectal cancer risk? BMC Cancer 2013; 13:214. [PMID: 23627542 PMCID: PMC3641950 DOI: 10.1186/1471-2407-13-214] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2013] [Accepted: 04/25/2013] [Indexed: 01/25/2023] Open
Abstract
Background Selenium has attracted attention because of its antioxidant properties. Antioxidants protects cells from damage. Certain breakdown products of selenium are believed to prevent tumor growth by enhancing the immune cell activity and suppressing the development of tumor blood vessels. In this observational study, selenium level was measured in a series of patients from Poland and Estonia to determine a correlation between levels of this microelement and colorectal cancer risk. Methods A total of 169 colorectal cancer patients and 169 healthy controls were enrolled in the study after obtaining their informed consent. Selenium level in the blood serum was measured using Graphite Furnace Atomic Absorption Spectrometry (GFAAS). The statistical analysis was performed by Fisher’s exact test. Results The threshold point of selenium level was 55 μg/l and 65 μg/l for Poland and Estonia respectively, for an increase in cancer risk. The lower levels of selenium were associated with greater risk of colorectal cancer. Conclusions The result reveals a significant strong association between low selenium level and the colorectal cancer risk in both Estonian and Polish populations.
Collapse
Affiliation(s)
- Marcin R Lener
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Połabska 4, 70-115 Szczecin, Poland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Lener M, Wiechowska-Kozłowska A, Kładny J, Muszyńska M, Sukiennicki G, Kubera-Nowakowska L, Lubiński J. Selenium and the risk of cancers of the colon, pancreas and stomach. Hered Cancer Clin Pract 2012. [PMCID: PMC3395400 DOI: 10.1186/1897-4287-10-s3-a13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
20
|
Lener M, Jakubowska A, Wiechowska-Kozłowska A, Kładny J, Muszyńska M, Sukiennicki G, Lubiński J. Selenium and gastrointestinal cancers risk. Hered Cancer Clin Pract 2012. [PMCID: PMC3518196 DOI: 10.1186/1897-4287-10-s4-a3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
21
|
Dymerska D, Fernández P, Suchy J, Pławski A, Słomski R, Kąklewski K, Scott RJ, Gronwald J, Kładny J, Byrski T, Huzarski T, Lubiński J, Kurzawski G. Combined iPLEX and TaqMan assays to screen for 45 common mutations in Lynch syndrome and FAP patients. Hered Cancer Clin Pract 2011. [PMCID: PMC3108174 DOI: 10.1186/1897-4287-9-s2-a9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
22
|
Trubicka J, Grabowska-Kłujszo E, Suchy J, Masojć B, Serrano-Fernandez P, Kurzawski G, Cybulski C, Górski B, Huzarski T, Byrski T, Gronwald J, Złowocka E, Kładny J, Banaszkiewicz Z, Wiśniowski R, Kowalska E, Lubinski J, Scott RJ. Variant alleles of the CYP1B1 gene are associated with colorectal cancer susceptibility. BMC Cancer 2010; 10:420. [PMID: 20701755 PMCID: PMC2929240 DOI: 10.1186/1471-2407-10-420] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2009] [Accepted: 08/11/2010] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND CYP1B1 is a P450 enzyme which is involved in the activation of pro-carcinogens to carcinogens as well as sex hormone metabolism. Because differences in the activity of the enzyme have been correlated with variant alleles of single nucleotide polymorphisms (SNPs), it represents an attractive candidate gene for studies into colorectal cancer susceptibility. METHODS We genotyped 597 cancer patients and 597controls for three CYP1B1 SNPs, which have previously been shown to be associated with altered enzymatic activity. Using the three SNPs, eight different haplotypes were constructed. The haplotype frequencies were estimated in cases and controls and then compared. The odds ratio for each tumour type, associated with each haplotype was estimated, with reference to the most common haplotype observed in the controls. RESULTS The three SNPs rs10012, rs1056827 and rs1056836 alone did not provide any significant evidence of association with colorectal cancer risk. Haplotypes of rs1056827 and rs10012 or rs1056827 and rs1056836 revealed an association with colorectal cancer which was significantly stronger in the homozygous carriers. One haplotype was under represented in the colorectal cancer patient group compared to the control population suggesting a protective effect. CONCLUSION Genetic variants within the CYP1B1 that are associated with altered function appear to influence susceptibility to a colorectal cancer in Poland. Three haplotypes were associated with altered cancer risk; one conferred protection and two were associated with an increased risk of disease. These observations should be confirmed in other populations.
Collapse
Affiliation(s)
- Joanna Trubicka
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Suchy J, Cybulski C, Wokołorczyk D, Oszurek O, Górski B, Debniak T, Jakubowska A, Gronwald J, Huzarski T, Byrski T, Dziuba I, Gogacz M, Wiśniowski R, Wandzel P, Banaszkiewicz Z, Kurzawski G, Kładny J, Narod SA, Lubiński J. CHEK2 mutations and HNPCC-related colorectal cancer. Int J Cancer 2010; 126:3005-9. [PMID: 19876921 DOI: 10.1002/ijc.25003] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Recently, the 1100delC variant of cell cycle checkpoint kinase 2 (CHEK2) has been reported to confer a colorectal cancer risk in hereditary non-polyposis-colorectal cancer (HNPCC) and HNPCC-related families in the Netherlands. To investigate whether CHEK2 mutations confer increased cancer risk in HNPCC and HNPCC-related families in Poland, we genotyped 463 probands from HNPCC and HNPCC-related families, and 5,496 controls for 4 CHEK2 alleles (1100delC, IVS2+1G>A, del5395, I157T). All 463 probands were screened for mutations in the HNPCC-related genes MSH2, MLH1 and MSH6. A positive association was observed for HNPCC-related cancer and the I157T missense CHEK2 mutation (OR = 1.7; p = 0.007), but not for the truncating alleles (OR = 1.0; p = 1.0). The association with the I157T was seen both for the 117 cases who fulfill Amsterdam criteria (OR = 1.9; p = 0.1) and for the 346 cases who do not fulfill the criteria (OR = 1.6; p = 0.03). One hundred forty-five of the 463 families had a mutation in MSH2, MLH1 or MSH6 (MMR-positive families). A positive association between the CHEK2 I157T mutation and HNPCC-related cancer was observed only for MMR-negative cases (OR = 2.1; p = 0.0004), but not for MMR-positive cases (OR = 0.8; p = 0.9). The association with I157T was particularly strong for MMR-negative cases with familial colorectal cancer (2 or more first-degree relatives affected) (OR = 2.5; p < 0.0001). We conclude that the I157T variant of CHEK2 increases the risk of colorectal cancer among MMR-negative, HNPCC/HNPCC-related families in Poland.
Collapse
Affiliation(s)
- Janina Suchy
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, il. Połabska 4, Szczecin, Poland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Dymerska D, Serrano-Fernández P, Suchy J, Pławski A, Słomski R, Kaklewski K, Scott RJ, Gronwald J, Kładny J, Byrski T, Huzarski T, Lubiński J, Kurzawski G. Combined iPLEX and TaqMan assays to screen for 45 common mutations in Lynch syndrome and FAP patients. J Mol Diagn 2009; 12:82-90. [PMID: 20007843 DOI: 10.2353/jmoldx.2010.090063] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Mutations of genes associated with the mismatch repair mechanism and mutations of the APC gene are the most frequent causes of hereditary colorectal cancer. An iPLEX test combined with TaqMan genotyping assays was therefore developed to identify common recurrent mutations of those genes in the Polish population. We analyzed 349 DNA samples from 95 positive controls previously identified by sequencing and 254 unexamined individuals. The iPLEX test included two plexes, which comprised seven mutations of the APC gene and 29 mutations of three of the mismatch repair genes. TaqMan assays were designed for nine mutations not covered by the iPLEX assays: one mutation in the APC gene and eight mutations in the mismatch repair genes. Results were then verified independently by sequencing. Our combination method allowed detection of all recurrent mutations occurring in group of patients, followed by full analysis by DNA sequencing. With the exception of one false positive in the iPLEX test in the positive control group that could be assigned to contamination from neighboring wells rather than a detection error, given sufficient DNA concentration and quality, the designed iPLEX/TaqMan test had an accuracy of 100% for the designed assays. These results suggest that the combined iPLEX/TaqMan test is an outstanding tool for identification of recurrent mutations among hereditary colorectal cancer patients.
Collapse
Affiliation(s)
- Dagmara Dymerska
- International Hereditary Cancer Center, Department of Genetics and Pathology, Pomeranian Medical University, Połabska 4 Street, 70-115 Szczecin, Poland.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
Gapska P, Scott RJ, Serrano-Fernandez P, Huzarski T, Byrski T, Kładny J, Gronwald J, Górski B, Cybulski C, Lubinski J, Dębniak T. Vitamin D receptor variants and breast cancer risk in the Polish population. Breast Cancer Res Treat 2008; 115:629-33. [DOI: 10.1007/s10549-008-0107-1] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2008] [Accepted: 06/13/2008] [Indexed: 10/21/2022]
|
26
|
Lubiński J, Korzeń M, Górski B, Cybulski C, Debniak T, Jakubowska A, Jaworska K, Wokołorczyk D, Medrek K, Matyjasik J, Huzarski T, Byrski T, Gronwald J, Masojć B, Lener M, Szymańska A, Szymańska-Pasternak J, Serrano-Fernàndez P, Piegat A, Uciński R, Domagała P, Domagała W, Chosia M, Kładny J, Górecka B, Narod S, Scott R. Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology. Breast Cancer Res Treat 2008; 114:121-6. [PMID: 18415014 DOI: 10.1007/s10549-008-9974-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2008] [Accepted: 03/06/2008] [Indexed: 11/30/2022]
Abstract
The aim of the study is to verify the hypothesis that genetic polymorphisms are associated with the predisposition to all malignancies. Using as a model breast cancers from the homogenous Polish population (West Pomeranian region) after stratification of 977 patients by age at diagnosis (under 51 years and above 50 years) and by tumour pathology (ductal cancers--low and high grade, lobular cancers, ER-positive/negative) we tested this hypothesis. Altogether 20 different groups of breast cancer cases have been analyzed. The results were compared to a group of unaffected controls that were matched by age, sex, ethnicity and geographical location and originated from families without cancers of any site among relatives. Molecular alterations selected for analyses included those which have been previously recognized as being associated with breast cancer predisposition. Statistically significant differences between the breast cancer cases and controls were observed in 19 of the 20 analyzed groups. Genetic changes were present in more than 90% of the breast cancer patients in 18 of 20 groups. The highest proportion of cases with constitutional changes-99.3% (139/140) was observed for lobular cancers. The number and type of genetic marker and/or the level of their association with the specific cancer predisposition was different between groups. Markers associated with majority of groups included: BRCA1, CHEK2, p53, TNRnTT, FGFRnAA, XPD CC/AA and XPD GG. Some markers appeared to be group specific and included polymorphisms in CDKN2A, CYP1B1, M3K nAA, and RS67.
Collapse
Affiliation(s)
- Jan Lubiński
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Polabska 4, 70-115, Szczecin, Poland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
27
|
Sulzyc-Bielicka V, Bińczak-Kuleta A, Pioch W, Kładny J, Gziut K, Bielicki D, Ciechanowicz A. 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients. Pharmacol Rep 2008; 60:238-242. [PMID: 18443386] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2007] [Revised: 11/29/2007] [Indexed: 05/26/2023]
Abstract
DPYD gene encodes dihydropyrimidine dehydrogenase which is the initial and rate-limiting enzyme in the metabolism of 5-fluorouracil (5-FU). The aim of our study was PCR-RFLP based-genetic testing for the most common 5-FU toxicity-attributable IVS14 + 1G > A DPYD mutation (DPYD(*)2A) in 252 Polish colorectal cancer (CRC) patients treated with this adjuvant chemotherapeutic regimen after surgery. The DPYD(*)2A allele was identified only in one patient: a male who was one of 4 CRC patients suffering from grades 3-4 myelotoxicity upon 5-FU chemotherapy. We conclude that IVS14 + 1G > A DPYD (DPYD(*)2A) variant occurs in the Polish population and is responsible for a significant proportion of life-threatening toxicity of 5-FU.
Collapse
Affiliation(s)
- Violetta Sulzyc-Bielicka
- Department of Oncological Surgery, Pomeranian Medical University, Powstańców Wlkp. 72, PL 70-111 Szczecin, Poznań, Poland
| | | | | | | | | | | | | |
Collapse
|
28
|
Debniak T, Scott RJ, Górski B, Cybulski C, van de Wetering T, Serrano-Fernandez P, Huzarski T, Byrski T, Nagay L, Debniak B, Kowalska E, Jakubowska A, Gronwald J, Wokolorczyk D, Maleszka R, Kładny J, Lubinski J. Common variants of DNA repair genes and malignant melanoma. Eur J Cancer 2007; 44:110-4. [PMID: 18024013 DOI: 10.1016/j.ejca.2007.10.006] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2007] [Revised: 09/12/2007] [Accepted: 10/09/2007] [Indexed: 01/07/2023]
Abstract
In the current study, we evaluated the possible associations of seven common variants of the DNA repair and cell cycle control genes BRCA2 and CHEK2 with malignant melanoma (MM). We genotyped 630 unselected MM patients and over 3700 controls (newborns, age- and sex-matched healthy adults with negative cancer family histories, and the adults selected at random by family doctors) for the prevalence of three common variants of the BRCA2 (T1915M, N991D and N372H) and four common variants of the CHEK2 (1100delC, VS2+1G --> A, I157T and del5395). Our study strongly suggests that the common variant of the BRCA2 gene -- the N991D variant is associated with malignant melanoma risk (OR=1.8, p=0.002 after Bonferroni correction). Patients homozygote for the N991D variant were present in 0.32% of cases and only 0.13% of controls. The other variants studied were not over-represented among MM patients when compared to the general population. In conclusion, we report an increased melanoma risk among carriers of the N991D change of the BRCA2 and no association of the CHEK2 changes with malignant melanoma.
Collapse
Affiliation(s)
- T Debniak
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Sulzyc-Bielicka V, Kuźna-Grygiel W, Kołodziejczyk L, Bielicki D, Kładny J, Stepień-Korzonek M, Telatyńska-Smieszek B. Cryptosporidiosis in Patients with Colorectal Cancer. J Parasitol 2007; 93:722-4. [PMID: 17626376 DOI: 10.1645/ge-1025r1.1] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Parasitological examination of feces was carried out for 55 patients with diagnosed colorectal cancer before chemotherapy. Except for Cryptosporidium sp., no other intestinal parasites were found in the specimens; moreover, only the patients with watery diarrhea were Cryptosporidium sp.-positive by enzyme immunoassay. Prevalence of infection in the group of patients with diarrhea (23 persons) was 43.5%, whereas it was 18% for the entire group of patients under study. Coproantigens of this parasite were detected primarily in the patients with tumors located on the left side (in the sigmoid and descending colon).
Collapse
Affiliation(s)
- V Sulzyc-Bielicka
- Department of Biology and Medical Parasitology, Pomeranian Medical University, Szczecin, Poland
| | | | | | | | | | | | | |
Collapse
|
30
|
Cybulski C, Gliniewicz B, Sikorski A, Kładny J, Huzarski T, Gronwald J, Byrski T, Debniak T, Gorski B, Jakubowska A, Wokolorczyk D, Narod SA, Lubiñski J. Epistatic Relationship between the Cancer Susceptibility Genes CHEK2 and p27. Cancer Epidemiol Biomarkers Prev 2007; 16:572-6. [PMID: 17372254 DOI: 10.1158/1055-9965.epi-06-0566] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
We studied the effects of p27 and CHEK2 variants on prostate and colon cancer risk in a case-control study. Modest effects on prostate cancer risk were observed for both CHEK2 missense and truncating variants. However, the excess cancer risk was restricted to the subgroup of men who were homozygous for the VV genotype in codon 109 of the p27 gene. Among men with the VV p27 genotype, the odds ratios associated with truncating and missense CHEK2 mutations were 3.1 (P < 0.0001) and 1.9 (P < 0.0001), respectively. Among men with other p27 genotypes (GG and VG), the odds ratios were 1.5 and 1.2 for truncating and missense CHEK2 mutations, respectively, and were not statistically significant. The interaction between CHEK2 and p27 was confirmed in a group of patients with colon cancer. Thus, it seems that the clinical expression of CHEK2 variant alleles on prostate and colon cancer risk may be restricted to individuals with a specific genotype (VV) of the p27 gene. Two-gene models provide numerous challenges for gene identification and cancer risk assessment.
Collapse
|
31
|
Debniak T, Scott R, Masojc B, Serrano-Fernández P, Huzarski T, Byrski T, Debniak B, Górski B, Cybulski C, Medrek K, Kurzawski G, van de Wetering T, Maleszka R, Kładny J, Lubinski J. MC1R common variants, CDKN2A and their association with melanoma and breast cancer risk. Int J Cancer 2006; 119:2597-602. [PMID: 16988943 DOI: 10.1002/ijc.22210] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
We sought to examine the association between MC1R variants and the risk of melanoma and breast cancer in Polish population. We also determined the prevalence of compound heterozygous carriers of MC1R and CDKN2A (A148T) variants. We examined 500 unselected melanoma cases, 511 consecutive invasive breast cancer patients, 800 newborns, 421 healthy adults matched for sex and age with the melanoma cases and 511 healthy women matched for sex and age with the breast cancer cases. A statistically significant association of all 4 MC1R variants with the melanoma risk was found. For the R151C variant p value was 0.000008 and odds ratio 2.9; for the V60L variant p value was 0.007 and OR 1.78; for the R160C p was 0.006 and OR 1.76; for the R163Q p was 0.015 and odds ratio 2.1. None of the compound heterozygotes were significantly over-represented among any of the melanoma cases, the highest OR (4.2) observed in patients harbouring the A148T variant in CDKN2A and the R151C variant in MC1R. Positive association was found between carrying any of the MC1R variants and (i) increased occurrence of melanoma among I degree relatives of the carriers; (ii) increased occurrence of melanoma on UV-non-exposed skin areas. We also observed a tendency of increased risk of multiple melanomas among carriers of MC1R variants. The haplotype analysis demonstrates that MC1R variants do not co-occur in cis, compound carriers have both alleles affected. We found no association with the MC1R variants and breast cancer risk. In conclusion, the results of this population-based study show herein that MC1R variants are associated with increased melanoma risk in the Polish population. The risk of disease seems to be increased additively for patients harbouring also the CDKN2A common variant A148T.
Collapse
Affiliation(s)
- Tadeusz Debniak
- Department of Genetics and Pathology, International Hereditary Cancer Centre, Pomeranian Medical University, Szczecin, Poland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Cybulski C, Wokołorczyk D, Kładny J, Kurzawski G, Kurzwaski G, Suchy J, Grabowska E, Gronwald J, Huzarski T, Byrski T, Górski B, D Ecedil Bniak T, Narod SA, Lubiński J. Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations? Eur J Hum Genet 2006; 15:237-41. [PMID: 17106448 DOI: 10.1038/sj.ejhg.5201734] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Germline mutations in cell cycle checkpoint kinase 2 (CHEK2) have been associated with a range of cancer types, in particular of the breast and prostate. Protein-truncating mutations in CHEK2 have been reported to confer higher risks of cancer of the breast and the prostate than the missense I157T variant. In order to estimate the risks of colorectal cancer associated with truncating and missense CHEK2 mutations, we genotyped 1085 unselected colorectal cancer cases and 5496 controls for four CHEK2 founder mutations present in Poland. We observed an increased risk of colorectal cancer in association with the missense I157T mutation (odds ratios (OR) = 1.5; 95% CI 1.2-2.0; P = 0.002) but not with truncating mutations (OR = 1.0; 95% CI 0.5-1.8; P = 0.9); however the difference in the two OR was not statistically significant (P = 0.2). We conclude that the I157T mutation increases the risk of colorectal cancer in the population, but that truncating mutations may confer a lower risk or no increase in risk. It is important that other studies of CHEK2 mutation carriers be conducted to confirm this hypothesis.
Collapse
|
33
|
Suchy J, Kurzawski G, Jakubowska K, Rać ME, Safranow K, Kładny J, Rzepka-Górska I, Chosia M, Czeszyńska B, Oszurek O, Scott RJ, Lubiński J. Frequency and nature of hMSH6 germline mutations in Polish patients with colorectal, endometrial and ovarian cancers. Clin Genet 2006; 70:68-70. [PMID: 16813607 DOI: 10.1111/j.1399-0004.2006.00630.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
|
34
|
Kurzawski G, Suchy J, Lener M, Kłujszo-Grabowska E, Kładny J, Safranow K, Jakubowska K, Jakubowska A, Huzarski T, Byrski T, Debniak T, Cybulski C, Gronwald J, Oszurek O, Oszutowska D, Kowalska E, Góźdź S, Niepsuj S, Słomski R, Pławski A, Łacka-Wojciechowska A, Rozmiarek A, Fiszer-Maliszewska Ł, Bebenek M, Sorokin D, Sasiadek MM, Stembalska A, Grzebieniak Z, Kilar E, Stawicka M, Godlewski D, Richter P, Brozek I, Wysocka B, Limon J, Jawień A, Banaszkiewicz Z, Janiszewska H, Kowalczyk J, Czudowska D, Scott RJ, Lubiński J. Germline MSH2 and MLH1 mutational spectrum including large rearrangements in HNPCC families from Poland (update study). Clin Genet 2006; 69:40-7. [PMID: 16451135 DOI: 10.1111/j.1399-0004.2006.00550.x] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Germline mutations in the DNA mismatch repair genes MSH2 and MLH1 account for a significant proportion of hereditary non-polyposis colorectal cancer (HNPCC) families. One approach by which development of an efficient DNA-testing procedure can be implemented is to describe the nature and frequency of common mutations in particular ethnic groups. Two hundred and twenty-six patients from families matching the Amsterdam II diagnostic criteria or suspected HNPCC criteria were screened for MSH2 and MLH1 germline mutations. Fifty different pathogenic mutations were found, 25 in MSH2 and 25 in MLH1. Twenty-four of these had not previously been described in other populations. Among our 78 families with MSH2 or MLH1 mutations, 54 (69.2%) were affected by recurrent mutations including 38 found at least twice in our own series. Two of the most frequent alterations were a substitution of A to T at the splice donor site of intron 5 of MSH2 and a missense change (A681T) of MLH1 found in 10 and eight families, respectively. Among large deletions detected by the multiplex ligation-dependent probe amplification assay, exon 9 deletions in the MSH2 gene were found in two families. Our results indicate that a screening protocol specific for the Polish population that is limited to the detection of all reported mutations will result in the identification of the majority of changes present in MLH1 and MSH2 genes in Polish HNPCC kindreds.
Collapse
Affiliation(s)
- G Kurzawski
- International Hereditary Cancer Center - Department of Genetics and Pathology, Universit of Szczecin and Pomeranian Medical University, Szczecin, Poland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Debniak T, Scott RJ, Huzarski T, Byrski T, Masojć B, van de Wetering T, Serrano-Fernandez P, Górski B, Cybulski C, Gronwald J, Debniak B, Maleszka R, Kładny J, Bieniek A, Nagay L, Haus O, Grzybowska E, Wandzel P, Niepsuj S, Narod SA, Lubinski J. XPD Common Variants and their Association with Melanoma and Breast Cancer Risk. Breast Cancer Res Treat 2006; 98:209-15. [PMID: 16685590 DOI: 10.1007/s10549-005-9151-2] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2005] [Accepted: 12/18/2005] [Indexed: 10/24/2022]
Abstract
There are suggestions in the literature that common variants in the XPD gene may be associated with an altered risk of melanoma and breast cancer. To establish if the XPD common variants Asp312Asn and Lys751Gln are associated with an increased melanoma or breast cancer risk we performed an association study based on genotyping 426 unselected patients with malignant melanoma (MM) and 1830 consecutive breast cancer cases and compared the results to 1262 geographically matched newborns, 621 adults from the region of Szczecin (unselected for age and cancer family history), 421 healthy adults age- and sex-matched with the melanoma cases and 511 healthy controls matched with the breast cancer patients from the region of Szczecin. Additionally we examined the prevalence of three additional XPD variants, Gly156Gly, Leu485Pro and Arg112His amongst the 421 unselected melanoma patients. All of the variants when evaluated singularly were found not to be associated either with melanoma or breast cancer risk in younger or older patients. A modest association was observed with breast cancer risk when the Lys751Gln_CC/Asp312Asn_AA genotype (OR=1.5, p<0.05) segregated together. Individuals harboring the Lys751Gln_CC/Gly156Gly_CC genotype were significantly over-represented among late-onset melanoma cases (OR=1.7, p<0.05). The results of analyses of linkage disequilibrium and haplotype frequency support the thesis that a combination of at least two SNPs (Lys751Gln_CC/Gly156Gly_CC or Lys751Gln_CC/Asp312Asn_AA) inherited as a haplotype was associated with disease. These two pairs of SNPs could therefore be regarded as a single hereditary unit that would have a very small probability of being disrupted by recombination. Additional studies are required to determine whether these particular changes can be associated with an increased risk of other malignancies at different sites of origin.
Collapse
Affiliation(s)
- T Debniak
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Kładny J. [Comment to the study: Metastasis to brain from rectal cancer as the first manifestation of neoplasmatic disease]. Wiad Lek 2006; 59:436. [PMID: 17017500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
|
37
|
Kurzawski G, Suchy J, Debniak T, Kładny J, Lubiński J. Importance of microsatellite instability (MSI) in colorectal cancer: MSI as a diagnostic tool. Ann Oncol 2005; 15 Suppl 4:iv283-4. [PMID: 15477322 DOI: 10.1093/annonc/mdh940] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Affiliation(s)
- G Kurzawski
- International Hereditary Cancer Center and Department of Genetic and Pathology of Pomeranian Medical University, Szczecin, Poland
| | | | | | | | | |
Collapse
|
38
|
Debniak T, Scott RJ, Huzarski T, Byrski T, Rozmiarek A, Debniak B, Załuga E, Maleszka R, Kładny J, Górski B, Cybulski C, Gronwald J, Kurzawski G, Lubinski J. CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res 2005; 65:835-9. [PMID: 15705881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/01/2023]
Abstract
The population frequencies of the CDKN2A variants remain undetermined. In Poland there are three common variants of CDKN2A: an alanine to threonine substitution (A148T), Nt500c>g and Nt540c>t, which have been detected in other populations. To establish if they are associated with an increased malignant melanoma (MM) risk we did an association study based on genotyping 471 patients with MM and 1,210 random control subjects from the same Polish population. We found a significantly increased frequency of the A148T variant among patients with MM (7.0%) in comparison with the general population (2.9%). The incidence of the A148T variant remained greater in both unselected and familial melanoma subgroups. A statistically significant positive association was seen for unselected MM (odds ratio, 2.529; P = 0.0003), especially in patients diagnosed under 50 years of age (odds ratio, 3.4; P = 0.0002). The A148T carrier population (heterozygous G/A alleles) was more likely to have a relative with malignancy compared with the noncarrier population (57% versus 36%, respectively; P = 0.03). Further examination of the CDKN2A promoter sequence done in 20 melanoma patients with the A148T change (heterozygous G/A alleles) and 20 patients with MM without this alteration identified it was in linkage disequilibrium with a polymorphism in the promoter region at position P-493. We found no statistically significant overrepresentation of the Nt500c>g and the Nt540c>t polymorphisms in the Polish melanoma population. In conclusion, the A148T variant of the CDKN2A gene seems to be associated with an increased risk of development of MM. Additional studies are required to confirm whether this particular change is associated with increased risk of other nonmelanoma malignancies.
Collapse
Affiliation(s)
- Tadeusz Debniak
- Departments of Genetics and Pathology, International Hereditary Cancer Center and Dermatology and Venerology, Pomeranian Medical University, Połabska 4, 70-115 Szczecin, Poland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
39
|
Wojtasik P, Al-Amawi T, Kładny J. [Stromal tumour of the small intestine as a rare cause of gastrointestinal bleeding]. Wiad Lek 2005; 58:350-2. [PMID: 16238132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/04/2023]
Abstract
The study presents a difficult to detect case of tumour of the small intestine in a 71-year-old patient. The first and only symptom of the sickness was gastrointestinal bleeding. Routine diagnostic methods failed to detect its source. Successful diagnosis was obtained only intraoperatively.
Collapse
Affiliation(s)
- Piotr Wojtasik
- Oddziału Klinicznego Chirurgii Onkologicznej Katedry Chirurgii Ogólnej i Naczyniowej Pomorskiej Akademii Medycznej w Szczecinie
| | | | | |
Collapse
|
40
|
Debniak T, Górski B, Cybulski C, Kurzawski G, Złowocka E, Kładny J, Chosia M, Lubiński J. Rarity of germline 1100delC mutation in CHK2 in patients with malignant melanoma of the skin. Melanoma Res 2004; 14:121-4. [PMID: 15057041 DOI: 10.1097/00008390-200404000-00007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
In this study the proportion of sporadic and familial malignant melanoma (MM) cases harbouring 1100delC in CHK2 was determined to assess whether this mutation is associated with the occurrence of MM. Three groups of patients were studied: (i) 101 patients with histologically confirmed sporadic MM of the skin diagnosed in the city of Szczecin, Poland; (ii) 16 MM patients with a family history of MM in their first-degree relatives; and (iii) 1024 individuals selected at random by family doctors from the city of Szczecin. Molecular examination included an allele-specific oligonucleotide polymerase chain reaction assay for the CHK2 founder mutation (1100delC), genomic sequencing, loss of heterozygosity analysis using CA-repeat microsatellite markers, and haplotype analysis. The CHK2 founder mutation was detected in one out of 101 (1%) of the sporadic MM cases, in none of the 16 familial MMs, and in two of the 1024 individuals (0.2%) from the general population. The differences between the groups of patients were not statistically significant. The MM patient with a CHK2 founder mutation was a 56-year-old female with a history of brain tumours at age 33 and 40 years, sarcoma at 41 years and finally MM at 55 years. Examination of tumorous DNA isolated from the MM and the sarcoma from this patient revealed no loss of heterozygosity in either tumour. It seems that examination of sporadic or familial MM cases for the 1100delC germline mutation in CHK2 is not justified. To evaluate whether this CHK2 founder mutation is associated with MM in patients with LFS syndrome, more MM cases from LFS families should be examined.
Collapse
Affiliation(s)
- Tadeusz Debniak
- Department of Genetics and Pathology, Pomeranian Academy of Medicine, Szczecin 70-111, Al. Powst. Wlkp. 72, Poland.
| | | | | | | | | | | | | | | |
Collapse
|
41
|
Kurzawski G, Suchy J, Kładny J, Grabowska E, Mierzejewski M, Jakubowska A, Debniak T, Cybulski C, Kowalska E, Szych Z, Domagała W, Scott RJ, Lubiński J. The NOD2 3020insC mutation and the risk of colorectal cancer. Cancer Res 2004; 64:1604-6. [PMID: 14996717 DOI: 10.1158/0008-5472.can-03-3791] [Citation(s) in RCA: 90] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Several predispositions to colorectal cancer have been identified, but little is known about genetic susceptibilities to disease in older persons. Colorectal cancer is a risk in Crohn's disease and is believed to be associated with an inappropriate inflammatory response. Recently, the NOD2 gene has been associated with Crohn's disease, which further strengthens the notion that the inflammatory response plays a crucial role in this disease. Several mutations have been identified in the NOD2 gene, which appear with significantly higher frequency in patients with the disease. One such mutation (3020insC) is believed to be clearly causative because it results in a prematurely truncated protein with a predicted reduction in functional efficiency. In this report, we have examined the frequency of the 3020insC mutation in a series of 856 individuals including 556 patients with colorectal cancer. The frequency of the 3020insC mutation in a consecutive series of 250 non-hereditary nonpolyposis colorectal cancer patients >50 years of age was significantly elevated compared with the control population (odds ratio, 2.23; P = 0.0046). The results indicate that NOD2 may be a predisposing factor to colorectal cancer characterized by an older average age of disease onset in persons who do not harbor any other genetic predisposition to disease.
Collapse
Affiliation(s)
- Grzegorz Kurzawski
- International Hereditary Cancer Center, Department of Genetics and Pathology, Szczecin, Poland.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Kładny J, Lichszteld K, Kołecki J. Decreased reactive oxygen generation during H2O2 decomposition in the presence of samples from human rectal cancer. Biopolymers 2004; 74:413-21. [PMID: 15222020 DOI: 10.1002/bip.20068] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Reactive oxygen species (ROS) have generated a great deal of interest in the clinical field since experimental studies showed the involvement of these species in carcinogenesis. This paper reports the detection of ROS during the decomposition of H2O2 in the presence of samples obtained from tissues of 16 patients with rectal carcinoma (age 64 +/- 9 years) operated on in the Division of Surgical Oncology of Pomeranian Medical University, Szczecin (Poland). The samples were cut from the middle of the resected tumors and from the colonic mucosa (10 cm distant from the tumor and free of disease); they were processed and the supernatants, representing the soluble fraction, were used for measurements. Various methods for measuring free radical activity of the examined samples were used, such as chemiluminescence, fluorescent probe 2',7'-dichlorodihydrofluorescein, spin trap 5,5-dimethyl-pyrroline-1-oxide and EPR, the spectrophotometrically examined formation of diformazan during reduction of the p-nitroblue tetrazolium salt, and bleaching of p-nitrosodimethylalanine. A statistically significant difference (P < 0.001) was noticed in mean chemiluminescence +/- standard error of the mean in the presence of the tumor samples (42.6 +/- 7.3) in comparison to the control samples (234.6 +/- 36.0). Significantly decreased generation of ROS from the decomposition of H2O2 in the presence of the tumor samples in comparison to the control samples was also observed when the above-mentioned methods were used. Tumor samples had significantly lower superoxide dismutase activity (33 +/- 4 U/mg protein) than controls (93 +/- 14 U/mg, P < 0.001), which should contribute to a lower capacity of endogenous H2O2 production and therefore less ROS generation upon H2O2 decomposition. We conclude that the tested samples have different redox properties; this supports a possible role of ROS activity during carcinogenesis. Moreover, we propose a new, simple, and sensitive chemiluminescent method, which might be effective in sample differentiation.
Collapse
Affiliation(s)
- Józef Kładny
- Division of Surgical Oncology, Pomeranian Medical University, Powstañców Wielkopolskich 72, 70-111 Szczecin, Poland
| | | | | |
Collapse
|
43
|
Kładny J, Möslein G, Myrhøj T, Kurzawski G, Jakubowska A, Dębniak T, Petriczko W, Kozłowski M, Al-Amawi T, Brzosko M, Fliciński J, Jawień A, Banaszkiewicz Z, Rychter P, Lubiński J. Nuclear Pedigree Criteria of Suspected HNPCC. Hered Cancer Clin Pract 2003. [PMCID: PMC2840011 DOI: 10.1186/1897-4287-1-1-34] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
The criteria for the diagnosis of HNPCC established by the ICG-HNPCC are very restrictive as they do not allow for the diagnosis of a large number of "suspected HNPCC" cases - these are families which do no fulfill the strict diagnostic "Amsterdam criteria", but do present with several pedigree and clinical features characteristic for HNPCC. Several series of families suspected of harboring germline mutations in DNA mismatch repair genes have been studied for germline changes in DNA mismatch repair genes and a mutation rate of somewhere between 8-60% was found. Therefore a subgroup of members of the ICG-HNPCC has been working on pedigree/clinical diagnostic criteria for suspected HNPCC. Materials and methods Results The combination of features - i.e. the occurrence of an HNPCC associated cancer (CRC or cancer of the endometrium, small bowel or urinary tract) in a 1st degree relative of a CRC patient; at least one of the patients being diagnosed under age of 50 - appeared to be strongly associated to HNPCC with an OR - 161. Constitutional mutations were identified in 18 (10 MLH1 and 8 MSH2 mutations) of 52 (34%) cases matching the above features. Conclusions The results of our studies strongly suggest that it is possible to diagnose HNPCC with a high degree of accuracy on the basis of nuclear pedigree data and clinical features.
Collapse
|
44
|
Debniak T, Górski B, Cybulski C, Jakubowska A, Kurzawski G, Lener M, Mierzejewski M, Masojć B, Medrek K, Kładny J, Załuga E, Maleszka R, Chosia M, Lubiński J. Germline 657del5 mutation in the NBS1 gene in patients with malignant melanoma of the skin. Melanoma Res 2003; 13:365-70. [PMID: 12883362 DOI: 10.1097/00008390-200308000-00005] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
In this study we determined in what proportion of consecutive malignant melanoma (MM) cases the 657del5 mutation of exon 6 of the NBS1 gene can be detected and whether it is associated with the occurrence of MM. Two groups of patients were studied: a series of 80 consecutive patients with histologically confirmed MM of the skin diagnosed in the city of Szczecin, Poland, and a series of 530 consecutive individuals selected at random by family doctors from the city of Szczecin. Molecular examination included an allele-specific polymerase chain reaction assay for the NBS1 founder mutation (657del5), genomic sequencing, loss of heterozygosity analysis using CA-repeat microsatellite markers, and haplotype analysis. The NBS1 founder mutation was detected in two of the 80 (2.5%) MM cases and in three of the 530 individuals (0.6%) from the general population. The difference was not statistically significant. However, examination of tumorous DNA from the patients with MM and NBS1 mutation revealed loss of heterozygosity in both cases. Haplotype analysis revealed that allellic loss affects wild-type alleles. Breast cancer was found in second-degree relatives of both MM probands with NBS1 mutations. One of these probands was simultaneously affected with breast cancer. It seems that the 657del5 mutation of exon 6 of NBS1 gene may be responsible for the occurrence of a small proportion of MM patients, characterized by the occurrence of breast cancer among their relatives.
Collapse
Affiliation(s)
- Tadeusz Debniak
- Department of Genetics, Pomeranian Academy of Medicine, Szczecin 70-111, Poland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Debniak T, Górski B, Cybulski C, Jakubowska A, Kurzawski G, Kładny J, Załuga E, Fiedorowicz J, Debniak B, Lubiński J. Increased risk of breast cancer in relatives of malignant melanoma patients from families with strong cancer familial aggregation. Eur J Cancer Prev 2003; 12:241-5. [PMID: 12771565 DOI: 10.1097/00008469-200306000-00013] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
The aim of this study was to evaluate the risk of occurrence of malignancies of different site of origin in patients with malignant melanoma (MM) of the skin and their first-degree relatives from families with cancer familial aggregations with unknown pathogenetic background (CFA). We analysed tumour spectrum and age at diagnosis of malignancies in 51 families with MM/CFA. In addition, we evaluated observed frequency (OF); expected frequency (EF); and relative risk (RR) of occurrence of malignancies in these families. In all cases peripheral blood examination of common Polish founder BRCA1 mutations was performed. In 25 families, we analysed loss of heterozygosity of BRCA1 and BRCA2 genes. We identified two subgroups of cases: 22 MM/CFA families with MM diagnosed before 55 years (< or =55 MM/CFA) and 29 MM/CFA families with MM diagnosed after 55 (>55 MM/CFA). In these families we observed increased proportion of breast cancers: 17.52% in the first subgroup (mean age of diagnosis 48.5) and 12.15% in the second subgroup. The odds ratio for breast tumours occurring before 50 in < or =55 MM/CFA families was 3.71. We also observed increased numbers of liver cancers, CSU and leukaemias. OF and EF analyses revealed increased risk of occurrence of cancers of breast (OF 10.4%, EF 4.5%) and liver (OF 1.9%, EF 0.8%) in women from MM/CFA families, RR for breast tumours was approximately 3.3 in < or =55 MM/CFA families. Molecular examination of MM/CFA families revealed no alterations within the BRCA2 gene and one germline mutation of the BRCA1 gene. In conclusion, it seems to be justified to consider systematic breast surveillance beginning at the age around 35-40 years as an option in women from < or =55 MM/CFA families.
Collapse
Affiliation(s)
- T Debniak
- Department of Genetics and Pathology, Pomeranian Academy of Medicine, Szczecin 70-111, Al.Powst.Wlkp.72, Poland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
46
|
Kurzawski G, Suchy J, Kładny J, Safranow K, Jakubowska A, Elsakov P, Kucinskas V, Gardovski J, Irmejs A, Sibul H, Huzarski T, Byrski T, Debniak T, Cybulski C, Gronwald J, Oszurek O, Clark J, Góźdź S, Niepsuj S, Słomski R, Pławski A, Łacka-Wojciechowska A, Rozmiarek A, Fiszer-Maliszewska Ł, Bebenek M, Sorokin D, Stawicka M, Godlewski D, Richter P, Brozek I, Wysocka B, Jawień A, Banaszkiewicz Z, Kowalczyk J, Czudowska D, Goretzki PE, Moeslein G, Lubiński J. Germline MSH2 and MLH1 mutational spectrum in HNPCC families from Poland and the Baltic States. J Med Genet 2002; 39:E65. [PMID: 12362047 PMCID: PMC1734972 DOI: 10.1136/jmg.39.10.e65] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Affiliation(s)
- G Kurzawski
- Hereditary Cancer Centre, Department of Genetics and Pathology, Pomeranian Academy of Medicine, Szczecin, Poland.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
The light emission from the adriamycin + Co2+ + H2O2 system has been studied. Chemiluminescence, fluorescence and absorption spectra were measured. The fluorescence spectra were time-dependent exhibiting maxima at 555, 590 and 645 nm. The chemiluminescence spectra consist of four bands with maxima at around 460-500, 550-580, 640 and 700 nm. Free radical reaction inhibitors, (1)O2-quenchers and catalase inhibited the light emission indicating that hydroxyl radical, superoxide anion radical and singlet oxygen are generated during the redox cycling of adriamycin. Chemiluminescence studies revealed that adriamycin undergoes chemiexcitation under our experimental conditions.
Collapse
Affiliation(s)
- I Kruk
- Institute of Physics, Technical University of Szczecin, Poland.
| | | | | | | |
Collapse
|
48
|
Bielicki D, Kładny J, Chosia M, Wawrzynowicz-Syczewska M, Starzyńska T. [A patient with abdominal actinomycosis--diagnostic problems]. Pol Merkur Lekarski 2000; 9:783-4. [PMID: 11204331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
Abstract
The difficulties in diagnosis of abdominal actinomycosis are presented. Clinical manifestations and colonoscopy suggested malignancy. Final diagnosis was made on the basis of pathological assessment of resected sigmoid. Authors underline that in case of "negative" pathomorphological results of material obtained during endoscopy from lesions suspected, benign disease should be consider including anctinomycosis and intraoperative pathomorphological examination should be performed.
Collapse
Affiliation(s)
- D Bielicki
- Katedry i Kliniki Chorób Zakaźnych Pomorskiej AM w Szczecinie
| | | | | | | | | |
Collapse
|
49
|
Bielicki D, Karbowniczek M, Sulzyc-Bielicka V, Kładny J, Boer C, Marlicz K, Domagała W. Clinico-pathological characteristics of colorectal cancer and serum anti-p53 antibodies. POL J PATHOL 1999; 50:77-81. [PMID: 10481530] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/13/2023] Open
Abstract
The purpose of this study was to correlate the presence of p53 antibodies in sera of patients with colorectal adenocarcinoma with size, site and stage of the tumour, age and sex of a patient and the level of carcinoembryonic antigen (CEA) in the serum. p53 antibodies were detected using enzyme-linked immunoabsorbent assay (ELISA). Serum p53 antibodies were detected in 30 of 145 patients (21%), mostly in Astler-Coller stage B1 (28% of patients). No association was found between p53 antibody status in stage A+B1+B2 vs stages C1+C2+D (22% vs 19%) i.e. between patients without and with metastases to regional lymph nodes and/or distant metastases. Serum p53 antibodies were detected in 9 of 34 patients (26%) with tumour localised in the right part vs 21 of 109 patients (19%) with tumours in the left part of the colon and in 18 of 96 (19%) of patients with tumours localised in rectosigmoideum vs 12 of 47 (26%) with tumours in the remaining colon. There was no significant correlation between serum anti p53 antibody and CEA statuses. Increased level of serum CEA was seen in 46/145 (32%) patients. Patients with C1+C2+D stage cancers had high serum CEA level more frequently than did patients with A+B1+B2 stage tumours (44% vs 19% respectively, p < 0.001). Of 102 cases with normal CEA level, 19 (19%) were positive for anti p53 antibodies. These results together with the literature data [11, 20] indicate that approximately 27% CEA negative patients may have serum p53 antibodies. Therefore simultaneous assessment of serum p53 antibodies and CEA seems to be useful for monitoring high risk patients and for postoperative patient monitoring.
Collapse
Affiliation(s)
- D Bielicki
- Department of Gastroenterology, Pomeranian Medical University, Szczecin
| | | | | | | | | | | | | |
Collapse
|
50
|
Gronwald J, Menkiszak J, Tołoczko A, Zajaczek S, Kładny J, Kurzawski G, Krzystolik K, Podolski J, Lubiński J. Hereditary breast cancer. POL J PATHOL 1998; 49:59-66. [PMID: 9798408] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023] Open
|